U.S. Markets closed

Rockwell Medical, Inc. (RMTI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3804-0.0126 (-3.21%)
At close: 04:00PM EST
0.3850 +0.00 (+1.21%)
After hours: 05:10PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3930
Bid0.3870 x 900
Ask0.3900 x 800
Day's Range0.3508 - 0.3889
52 Week Range0.3400 - 1.9800
Avg. Volume2,437,375
Market Cap35.745M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.3460
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea

    Two product forms of Triferic® are now approved in South KoreaWIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyr


    The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical

    VANCOUVER, BC / ACCESSWIRE / January 14, 2022 / The Power Play by The Market Herald has announced the release of new interviews with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical discussing their latest press releases.The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

  • Benzinga

    Rockwell Medical Shares Surge On South Korean Approval For Iron Supplementation Therapy

    Rockwell Medical Inc's (NASDAQ: RMTI) partner, Jeil Pharmaceutical Co Ltd, has received regulatory approval in South Korea for Triferic Injection for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil to commercialize Triferic in South Korea. Regarding the license, Rockwell Medical has received an upfront fee and will be eligible for milestone payments and roya